Mirum Pharmaceuticals (MIRM) Receivables (2021 - 2026)

Mirum Pharmaceuticals has reported Receivables for 6 years, with the latest figure at $133.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 38.87% year-over-year to $133.1 million; the trailing twelve-month figure through Mar 2026 stood at $133.1 million (up 38.87% YoY), and the FY2025 full-year result was $123.3 million, up 57.54% from the prior year.
• Receivables for Q1 2026 stood at $133.1 million, up from $123.3 million in the prior quarter.
• The five-year high for Receivables was $133.1 million in Q1 2026, with the low at $7.9 million in Q1 2022.
• Average Receivables over 5 years is $62.7 million, with a median of $60.4 million recorded in 2024.
• Year-over-year, Receivables surged 3984.25% in 2022 and rose 15.18% in 2024.
• Tracing MIRM's Receivables over 5 years: stood at $24.0 million in 2022, then surged by 183.27% to $68.0 million in 2023, then increased by 15.18% to $78.3 million in 2024, then soared by 57.54% to $123.3 million in 2025, then climbed by 7.93% to $133.1 million in 2026.
• The last three Receivables figures came in at $133.1 million (Q1 2026), $123.3 million (Q4 2025), and $107.1 million (Q3 2025), per Business Quant data.

Peer Comparison